Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1029-1034

  Fletcher, Courtney V ^a,c   Brundage, Richard C ^a   Remmel, Rory P ^a   Page, Linda M ^a   Weller, Dennis ^a   Calles, Nancy R ^b   Simon, Cara ^b   Kline, Mark W ^b  

^a University of Minnesota   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; PROTEINASE INHIBITOR; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDANOSINE; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV INFECTIONS; HUMANS; INDINAVIR; SPECTROPHOTOMETRY, ULTRAVIOLET; STAVUDINE; TIME FACTORS;

EID: 0034065983     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1029-1034.2000     Document Type: Article

References (14)

1. Acosta, E. P., K. Henry, L. Baken, L. M. Page, and C. V. Fletcher. 1999. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
2. Balis, F. M., P. A. Pizzo, K. M. Butler, M. E. Hawkins, P. Brouwers, R. N. Husson, F. Jacobsen, S. M. Blaney, J. Gress, P. Jarosinski, and D. G. Poplack. 1992. Clinical pharmacology of 2′-3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165:99-104.
3. Butler, K. M., R. N. Husson, F. M. Balis, P. Brouwers, J. Eddy, D. El-Amin, J. Gress, M. Hawkins, P. Jarosinski, H. Moss, D. Poplack, S. Santacroce, D. Venzon, L. Weiner, P. Wolters, and P. A. Pizzo. 1991. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N. Eng. J. Med. 324:137-144.
4. Centers for Disease Control and Prevention. 1994. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbid. Mortal. Weekly Rep. 43(RR-12):1-10.
5. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morbid. Mortal. Weekly Rep. 47(RR-4):1-43.
6. Harris, M., C. Durakovic, S. Rae, J. Raboud, S. Fransen, A. Shillington, B. Conway, and J. S. G. Montaner. 1998. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J. Infect. Dis. 177:1514-1520.
7. Kline, M. W., L. M. Dunkle, J. A. Church, J. C. Goldsmith, A. T. Harris, M. E. Federici, M. E. Schnitze, L. Woods, D. F. Loewen, S. Kaul, A. Cross, V. L. Rutkiewicz, H. M. Rosenblatt, I. C. Hanson, and W. T. Shearer. 1995. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247-252.
8. Kline, M. W., C. V. Fletcher, M. E. Federici, A. T. Harris, K. D. Evans, V. L. Rutkiewicz, W. T. Shearer, and L. M. Dunkle. 1996. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 97:886-890.
9. Kline, M. W., C. V. Fletcher, A. T. Harris, K. D. Evans, R. C. Brundage, R. P. Remmel, N. R. Calles, S. B. Kirkpatrick, and C. Simon. 1998. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J. Pediatr. 132:543-546.
10. Mueller, B. U., K. M. Butler, V. L. Stocker, F. M. Balis, P. Brouwers, P. Jarosinski, R. N. Husson, L. L. Lewis, D. Venzon, and P. A. Pizzo. 1994. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 94:724-731.
11. Mueller, B. U., J. Sleasman, R. P. Nelson, S. Smith, P. J. Deutsch, W. Ju, S. M. Steinberg, F. M. Balis, P. F. Jarosinski, P. Brouwers, G. Mistry, G. Winchell, S. Zwerski, S. Sei, L. V. Wood, S. Zeichner, and P. A. Pizzo. 1998. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 102:101-109.
12. Mueller, B. U., S. L. Zeichner, V. A. Kuznetsov, M. Heath-Chiozzi, P. A. Pizzo, and D. S. Dimitrov. 1998. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 12:F191-F196.
13. NONMEM Project Group. 1991. NONMEM user's guide, parts I-VI. Division of Clinical Pharmacology, University of California at San Francisco, San Francisco.
14. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24 week open label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.